Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.

The financing round was led by Swisscanto Invest by Zürcher Kantonalbank and joined by Waters Corporation as well as existing private investors. Upon the first closing, Robert Schier of Swisscanto Invest joined the board of directors. The Series C financing round brings the total amount raised by Creoptix AG to more than CHF15m. Creoptix said, it will use the proceeds to strengthen its commercial operations in Europe and the US.

Read More